Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Minerva Neurosciences Inc is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Minerva Neurosciences employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.74 |
|---|---|
| 52-week range | $0.71 - $3.69 |
| 50-day moving average | $0.95 |
| 200-day moving average | $1.81 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.84 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.7398 from 2022-01-27
| 1 week (2022-01-19) | -9.47% |
|---|---|
| 1 month (2021-12-24) | N/A |
| 3 months (2021-10-28) | -46.00% |
| 6 months (2021-07-28) | -61.27% |
| 1 year (2021-01-28) | -76.74% |
|---|---|
| 2 years (2020-01-28) | -91.29% |
| 3 years (2019-01-28) | 6.45 |
| 5 years (2017-01-27) | 10.75 |
Valuing Minerva Neurosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Minerva Neurosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Minerva Neurosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.6 million.
The EBITDA is a measure of a Minerva Neurosciences's overall financial performance and is widely used to measure a its profitability.
| Gross profit TTM | $19.1 million |
|---|---|
| Return on assets TTM | -24.03% |
| Return on equity TTM | -83.45% |
| Profit margin | 0% |
| Book value | $0.66 |
| Market capitalisation | $31.2 million |
TTM: trailing 12 months
We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.
Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $0.71 up to $3.693. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 0.886. This would suggest that Minerva Neurosciences's shares are less volatile than average (for this exchange).
Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.